616 related articles for article (PubMed ID: 18323509)
1. Trends in usage of alternative antiplatelet therapy after stroke and transient ischemic attack.
Hills NK; Johnston SC
Stroke; 2008 Apr; 39(4):1228-32. PubMed ID: 18323509
[TBL] [Abstract][Full Text] [Related]
2. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.
Serebruany VL; Malinin AI; Pokov AN; Hanley DF
Clin Ther; 2008 Feb; 30(2):249-59. PubMed ID: 18343263
[TBL] [Abstract][Full Text] [Related]
3. Combination antiplatelet agents for secondary prevention of ischemic stroke.
Vande Griend JP; Saseen JJ
Pharmacotherapy; 2008 Oct; 28(10):1233-42. PubMed ID: 18823219
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of ex vivo high on-treatment platelet reactivity on antiplatelet therapy after transient ischemic attack or ischemic stroke on the PFA-100(®) and VerifyNow(®).
Kinsella JA; Tobin WO; Cox D; Coughlan T; Collins R; O'Neill D; Murphy RP; McCabe DJ
J Stroke Cerebrovasc Dis; 2013 Oct; 22(7):e84-92. PubMed ID: 22981273
[TBL] [Abstract][Full Text] [Related]
5. Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease.
Tran H; Anand SS
JAMA; 2004 Oct; 292(15):1867-74. PubMed ID: 15494585
[TBL] [Abstract][Full Text] [Related]
6. Antiplatelet Therapy After Noncardioembolic Stroke.
Greving JP; Diener HC; Reitsma JB; Bath PM; Csiba L; Hacke W; Kappelle LJ; Koudstaal PJ; Leys D; Mas JL; Sacco RL; Algra A
Stroke; 2019 Jul; 50(7):1812-1818. PubMed ID: 31177983
[TBL] [Abstract][Full Text] [Related]
7. Antiplatelet therapy in ischemic stroke: variability in clinical trials and its impact on choosing the appropriate therapy.
Biller J
J Neurol Sci; 2009 Sep; 284(1-2):1-9. PubMed ID: 19380153
[TBL] [Abstract][Full Text] [Related]
8. Balancing Benefits and Risks of Long-Term Antiplatelet Therapy in Noncardioembolic Transient Ischemic Attack or Stroke.
Hilkens NA; Algra A; Diener HC; Bath PM; Csiba L; Hacke W; Kappelle LJ; Koudstaal PJ; Leys D; Mas JL; Sacco RL; Greving JP
Stroke; 2021 Oct; 52(10):3258-3265. PubMed ID: 34304604
[TBL] [Abstract][Full Text] [Related]
9. Rapid change in prescribing behavior in hospitals participating in get with the guidelines-stroke after release of the management of atherothrombosis with clopidogrel in high-risk patients (MATCH) clinical trial results.
Menon BK; Frankel MR; Liang L; Labresh KA; Ellrodt G; Hernandez AF; Fonarow GC; Schwamm LH; Smith EE;
Stroke; 2010 Sep; 41(9):2094-7. PubMed ID: 20634476
[TBL] [Abstract][Full Text] [Related]
10. Antiplatelet therapy in cerebrovascular disease: implications of Management of Artherothrombosis with Clopidogrel in High-risk Patients and the Clopidogrel for High Artherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance studies' results for cardiologists.
Fintel DJ
Clin Cardiol; 2007 Dec; 30(12):604-14. PubMed ID: 17847044
[TBL] [Abstract][Full Text] [Related]
11. New insights in antiplatelet therapy for patients with ischemic stroke.
Chaturvedi S; Bhattacharya P
Neurologist; 2011 Sep; 17(5):255-62. PubMed ID: 21881467
[TBL] [Abstract][Full Text] [Related]
12. Secondary stroke prevention with antiplatelet drugs: have we reached the ceiling?
Diener HC
Int J Stroke; 2006 Feb; 1(1):4-8. PubMed ID: 18706062
[TBL] [Abstract][Full Text] [Related]
13. A randomised controlled trial of triple antiplatelet therapy (aspirin, clopidogrel and dipyridamole) in the secondary prevention of stroke: safety, tolerability and feasibility.
Sprigg N; Gray LJ; England T; Willmot MR; Zhao L; Sare GM; Bath PM
PLoS One; 2008 Aug; 3(8):e2852. PubMed ID: 18682741
[TBL] [Abstract][Full Text] [Related]
14. Secondary stroke prevention with antiplatelet therapy with emphasis on the cardiac patient: a neurologist's view.
Gebel JM
J Am Coll Cardiol; 2005 Sep; 46(5):752-5. PubMed ID: 16139120
[TBL] [Abstract][Full Text] [Related]
15. MATCH results: implications for the internist.
Lutsep HL
Am J Med; 2006 Jun; 119(6):526.e1-7. PubMed ID: 16750967
[TBL] [Abstract][Full Text] [Related]
16. Review of antiplatelet therapy in secondary prevention of cerebrovascular events: a need for direct comparisons between antiplatelet agents.
Jamieson DG; Parekh A; Ezekowitz MD
J Cardiovasc Pharmacol Ther; 2005 Sep; 10(3):153-61. PubMed ID: 16211203
[TBL] [Abstract][Full Text] [Related]
17. [Antithrombotic therapy in ischemic stroke and transient ischemic attack].
Overgaard K; Poulsen TS; Husted SE
Ugeskr Laeger; 2007 Oct; 169(40):3379-82. PubMed ID: 17953858
[TBL] [Abstract][Full Text] [Related]
18. Evolving perspectives on clopidogrel in the treatment of ischemic stroke.
Gorelick P; Sechenova O; Hennekens CH
J Cardiovasc Pharmacol Ther; 2006 Dec; 11(4):245-8. PubMed ID: 17220470
[TBL] [Abstract][Full Text] [Related]
19. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS).
Diener HC; Sacco R; Yusuf S; ;
Cerebrovasc Dis; 2007; 23(5-6):368-80. PubMed ID: 17337887
[TBL] [Abstract][Full Text] [Related]
20. [Secondary prevention with clopidogrel after TIA or stroke].
Zuurbier SM; Vermeer SE; Hilkens PH; Algra A; Roos YB
Ned Tijdschr Geneeskd; 2013; 157(25):A5836. PubMed ID: 23777963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
